Accelerating Discoveries Into Medicines
Our Mission
The Stanford Innovative Medicines Accelerator (IMA) seeks to accelerate the translation of Stanford research discoveries into new medicines while expanding our knowledge of human biology.
A Differentiated Approach
The IMA transforms biomedical discoveries at Stanford into promising medicines. Projects enter the IMA superhighway through competitive project selection. Each project is matched with in-house industry experts who, bolstered by world-class facilities and scaling partners, help those projects navigate the landscape of translation, providing the best chance of success. This acceleration harnesses Stanford’s collaborative prowess in translational and clinical research and the scaling capabilities of our strong external alliances to democratize drug development and de-risk investments in potentially transformative new medicines. Our pipeline is diverse in disease areas and modalities, with projects that range from small molecules to gene therapies, from infectious diseases to oncology.
Success Stories
Projects supported by the IMA have the potential to transform medicine. Learn about some of the products that exited our pipeline.
Pediatric matched stem cell and organ transplant therapy
Entrepreneur-in-residence launches cancer biotech
New company tricks cancer cells into self-destructing
Nobel laureate launches startup for new cancer immunotherapy
New hope from old drugs for cystic fibrosis: startup explores combination therapy
New depression biomarker enables clinical trial in precision therapies
COVID-19 study sparks new company exploring first-in-class medicines for rare pulmonary diseases
New stable and affordable COVID vaccine could revolutionize global vaccine distribution
New drug candidate could make existing cancer immunotherapies more effective
Funding Opportunities
Ensuring Impact
The IMA engages with diverse partners who help realize the full potential of these projects. These alliances ensure that our road-tested, validated prototypes continue on their path to patients beyond the walls of Stanford.
